Article
Immunology
Paola Antonello, Diego U. Pizzagalli, Mathilde Foglierini, Serena Melgrati, Egle Radice, Sylvia Thelen, Marcus Thelen
Summary: Chemotaxis is an essential process in tumors metastasis, and in this study, ACKR3 was found to control the migration of lymphoma cells in response to CXCL12. The interaction between LTB4 and CXCL12 enhances the migration of lymphoma cells, providing a novel mechanism for cell-to-cell-induced migration.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Martine J. Smit, Geraldine Schlecht-Louf, Maria Neves, Jelle van den Bor, Petronila Penela, Marco Siderius, Francoise Bachelerie, Federico Mayor
Summary: The elevated expression of chemokine receptors CXCR4 and ACKR3 and their ligand CXCL12 in tumors and the tumor microenvironment has led to complex research on their contribution to cancer pathogenesis. Discussions include their impact on signaling networks, crosstalk with RTKs and other TME factors, as well as the infiltration of immune cells supporting tumor progression. Targeting the CXCL12/CXCR4/ACKR3 axis along with RTKs and immune cells modulation shows promising therapeutic potential in multitargeted cancer therapies.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021
(2021)
Article
Medicine, Research & Experimental
Marius E. Mayerhoefer, Markus Raderer, Wolfgang Lamm, Verena Pichler, Sarah Pfaff, Michael Weber, Barbara Kiesewetter, Markus Hacker, Lukas Kazianka, Philipp B. Staber, Hans-Juergen Wester, Johannes Rohrbeck, Ingrid Simonitsch-Klupp, Alexander Haug
Summary: In this prospective study, [Ga-68]Pentixafor-PET showed higher sensitivity and detection rates compared to [F-18]FDG-PET in patients with mantle cell lymphoma (MCL), indicating that it may be a potential alternative for imaging in these patients. The study also found that SUVs and TBRs were significantly higher for [Ga-68]Pentixafor-PET, with the most notable difference observed in mean TBRblood values.
Review
Endocrinology & Metabolism
Vincent Duval, Paul Alayrac, Jean-Sebastien Silvestre, Angelique Levoye
Summary: Chemokines and their receptors play a crucial role in cardiovascular diseases. ACKR3, as an atypical chemokine receptor, has an exclusive role in CVD. Better understanding of ACKR3's precise functions may lead to the development of novel therapeutic strategies.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Kento Takaya, Toru Asou, Kazuo Kishi
Summary: The accumulation of senescent cells in aging tissues is associated with age-related diseases and functional decline. A study found that atypical chemokine receptor 3 (ACKR3) is selectively expressed on the surface of senescent human fibroblasts. This discovery allows for the selective elimination of senescent cells and could contribute to the development of novel senolysis approaches.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Maria Neves, Viviana Marolda, Federico Mayor, Petronila Penela
Summary: A better understanding of the crosstalk between key receptors and signaling pathways involved in cancer progression, specifically in breast cancer subtypes, is crucial for improving current therapies and addressing tumor microenvironment. This study examines the interplay between CXCR4/ACKR3 chemokine receptors and EGFR family signaling pathways in different breast cancer cell models and highlights their cooperation in promoting ERK1/2 activation, with potential implications for cancer progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Andreas K. Buck, Goetz Ulrich Grigoleit, Sabrina Kraus, Andreas Schirbel, Michael Heinsch, Niklas Dreher, Takahiro Higuchi, Constantin Lapa, Heribert Haenscheid, Samuel Samnick, Hermann Einsele, Sebastian E. Serfling, Rudolf A. Werner
Summary: In this study, we investigated the use of CXCR4-targeted radioligand therapy (RLT) as a conditioning regimen for hematopoietic stem cell transplantation (HSCT) in patients with advanced T-cell lymphoma. The results showed that CXCR4-directed RLT can be an effective treatment option, leading to remarkable antilymphoma activity in selected cases.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Cell Biology
Kathryn E. Luker, Gary D. Luker
Summary: This study reveals the regulation of PKM2 and cellular metabolism by CXCL12 signaling through CXCR4 and ACKR3, leading to the dissociation of PKM2 from beta-arrestin 2 and a shift in its oligomerization state.
Article
Multidisciplinary Sciences
Eva M. Garcia-Cuesta, Jose Miguel Rodriguez-Frade, Sofia R. Gardeta, Gianluca D'Agostino, Pablo Martinez, Blanca Soler Palacios, Graciela Cascio, Tobias Wolf, Nicolas Mateos, Rosa Ayala-Bueno, Cesar A. Santiago, Pilar Lucas, Lucia Llorente, Luis M. Allende, Luis Ignacio Gonzalez-Granado, Noa Martin-Cofreces, Pedro Roda-Navarro, Federica Sallusto, Francisco Sanchez-Madrid, Maria F. Garcia-Parajo, Laura Martinez-Munoz, Mario Mellado
Summary: This study reveals that the truncated mutant chemokine receptor CXCR4(R334X) associated with WHIM syndrome fails to nanoclusterize after CXCL12 stimulation, affecting cell spatial organization and mobility, and causing multiple phalloidin-positive protrusions in cells. The inappropriate activation of beta-arrestin1 by CXCR4(R334X) leads to inadequate actin cytoskeleton remodeling, disrupting the balance between activated and deactivated cofilin.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Multidisciplinary Sciences
Elena C. Sigmund, Lilian Baur, Philipp Schineis, Jorge Arasa, Victor Collado-Diaz, Martina Vranova, Rolf A. K. Stahl, Marcus Thelen, Cornelia Halin
Summary: ACKR3 is a scavenging receptor implicated in lymphatic development, with deficiency leading to lymphatic hyperplasia and cardiac defects in mice. However, in adult mice, LEC-expressed ACKR3 does not contribute to postnatal lymphangiogenesis or lymphatic function.
Article
Pathology
Natalia Rusetska, Kamil Kowalski, Kamil Zalewski, Sebastian Zieba, Mariusz Bidzinski, Krzysztof Goryca, Beata Kotowicz, Malgorzata Fuksiewicz, Janusz Kopczynski, Elwira Bakula-Zalewska, Artur Kowalik, Magdalena Kowalewska
Summary: The study found that the CXCR4/ACKR3/CXCL12 axis is activated during progression and lymphatic spread of VSCC. CXCR4 and ACKR3 proteins are nearly absent in precancerous lesions but are strong in VSCC samples. Additionally, serum CXCL12 levels are significantly increased in both patients with VSCC and premalignant vulvar lesions.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Article
Oncology
Tessa Skroblyn, Jara J. Joedicke, Madlen Pfau, Kerstin Krueger, Jean-Pierre Bourquin, Shai Izraeli, Cornelia Eckert, Uta E. Hoepken
Summary: The study identified CXCL12-CXCR4 as the leading signaling axis for B-ALL cell migration and survival in the testicular leukemic niche. CXCR4 was found to be the only chemokine receptor robustly expressed on B-ALL cells in both diagnosis and relapse samples. Blocking CXCR4 functions showed promising results in preventing testicular infiltration and overall development of leukemia.
JOURNAL OF PATHOLOGY
(2022)
Review
Oncology
Tiina Juntikka, Samuli Vaittinen, Tero Vahlberg, Sirkku Jyrkkio, Heikki Minn
Summary: SSTR2 and CXCR4 are commonly found in DLBCL, FL, and HL, with frequent co-expression in these cases. However, the expression of SSTRs and CXCR4 is heterogeneous and very low in some subtypes such as MCL and MALT, while some patients show abundant expression, making them potential candidates for future trials of SSTR2 and/or CXCR4 targeted treatments.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Isabel Hamshaw, Marco M. D. Cominetti, Wing-Yee Lai, Mark Searcey, Anja Mueller
Summary: Cancer metastasis is a major cause of cancer-related death. The CXCR4 receptor and its ligand CXCL12 play important roles in promoting metastasis, making them attractive therapeutic targets. In this study, a novel CXCR4 antagonist was developed and used for CXCR4-based imaging. The results showed that these antagonists were non-toxic and effectively inhibited cancer cell migration and calcium release.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Alp Bayrak, Florian Mohr, Kyra Kolb, Martyna Szpakowska, Ekaterina Shevchenko, Valerie Dicenta, Anne-Katrin Rohlfing, Mark Kudolo, Tatu Pantsar, Marcel Guenther, Agnieszka A. Kaczor, Antti Poso, Andy Chevigne, Thanigaimalai Pillaiyar, Meinrad Gawaz, Stefan A. Laufer
Summary: This study reports the discovery and development of first-in-class ACKR3 agonists, which demonstrated superagonistic properties in a fi-arrestin recruitment assay. Through structure-activity relationship studies, novel compounds with selective activity against ACKR3 were identified, showing potential as candidates for the treatment of platelet-mediated thrombosis.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
M. Chiappa, F. Guffanti, F. Bertoni, I. Colombo, G. Damia
Summary: Ovarian cancer, particularly high grade serous carcinoma (HGSOC), is associated with deficiency in homologous recombination (HR) and often involves loss of function of BRCA1 or BRCA2 genes. Inhibition of poly-ADP-ribose polymerase (PARP) is synthetic lethal with HR deficiency and has significantly improved outcomes in HGSOC patients, although resistance to PARP inhibitors is common. Various mechanisms of resistance include upregulation of efflux pumps, mutations in PARP1 protein, restoration of HR, and protection of the replicative fork. Understanding these mechanisms is crucial for developing new treatment strategies for individual HGSOC patients.
DRUG RESISTANCE UPDATES
(2021)
Article
Multidisciplinary Sciences
Tiziano Bernasocchi, Geniver El Tekle, Marco Bolis, Azzurra Mutti, Arianna Vallerga, Laura P. Brandt, Filippo Spriano, Tanya Svinkina, Marita Zoma, Valentina Ceserani, Anna Rinaldi, Hana Janouskova, Daniela Bossi, Manuela Cavalli, Simone Mosole, Roger Geiger, Ze Dong, Cai-Guang Yang, Domenico Albino, Andrea Rinaldi, Peter Schraml, Simon Linder, Giuseppina M. Carbone, Andrea Alimonti, Francesco Bertoni, Holger Moch, Steven A. Carr, Wilbert Zwart, Marianna Kruithof-de Julio, Mark A. Rubin, Namrata D. Udeshi, Jean-Philippe P. Theurillat
Summary: Mutually exclusive prostate cancer driver alterations involving ERG transcription factor and ubiquitin ligase adaptor SPOP have synthetic sick effects, regulating the response to therapeutic interventions in the AR pathway. This dichotomy highlights a distinct class of antagonistic cancer drivers and provides a blueprint for therapeutic exploitation.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Silvia Pietrobono, Eugenio Gaudio, Sinforosa Gagliardi, Mariapaola Zitani, Laura Carrassa, Francesca Migliorini, Elena Petricci, Fabrizio Manetti, Nikolai Makukhin, Adam G. Bond, Brooke D. Paradise, Alessio Ciulli, Martin E. Fernandez-Zapico, Francesco Bertoni, Barbara Stecca
Summary: The study identified a novel mechanism involving the SOX2-BRD4 transcriptional complex driving the expression of GLI1, an effector in the HH/GLI pathway, independently of SMO activation. Combining a SMO inhibitor with a BRD4 degrader showed synergistic anti-proliferative effects in melanoma cells, providing a new potential treatment strategy for melanomas with an active SOX2-BRD4-GLI1 axis.
Review
Environmental Sciences
Ana Rotter, Michele Barbier, Francesco Bertoni, Atle M. Bones, M. Leonor Cancela, Jens Carlsson, Maria F. Carvalho, Marta Ceglowska, Jeronimo Chirivella-Martorell, Meltem Conk Dalay, Mercedes Cueto, Thanos Dailianis, Irem Deniz, Ana R. Diaz-Marrero, Dragana Drakulovic, Arita Dubnika, Christine Edwards, Hjoerleifur Einarsson, Aysegul Erdogan, Orhan Tufan Eroldogan, David Ezra, Stefano Fazi, Richard J. FitzGerald, Laura M. Gargan, Susana P. Gaudencio, Marija Gligora Udovic, Nadica Ivosevic DeNardis, Rosa Jonsdottir, Marija Katarzyte, Katja Klun, Jonne Kotta, Leila Ktari, Zrinka Ljubesic, Lada Lukic Bilela, Manolis Mandalakis, Alexia Massa-Gallucci, Inga Matijosyte, Hanna Mazur-Marzec, Mohamed Mehiri, Soren Laurentius Nielsen, Lucie Novoveska, Donata Overlinge, Giuseppe Perale, Praveen Ramasamy, Celine Rebours, Thorsten Reinsch, Fernando Reyes, Baruch Rinkevich, Johan Robbens, Eric Roettinger, Vita Rudovica, Jerica Sabotid, Ivo Safarik, Siret Talve, Deniz Tasdemir, Xenia Theodotou Schneider, Olivier P. Thomas, Anna Torunska-Sitarz, Giovanna Cristina Varese, Marlen Vasquez
Summary: Coastal countries have traditionally relied on marine resources for various needs, while modern societies have increased demands for diverse products leading to the emergence of blue biotechnology. This field offers opportunities for commercial interests in pharmaceuticals, cosmetics, food, and related industries. Exploration of marine resources and their potential applications in various sectors are highlighted, along with the importance of legislation, funding, communication, and stakeholder engagement in the development of marine biotechnology.
FRONTIERS IN MARINE SCIENCE
(2021)
Article
Veterinary Sciences
Luca Aresu, Chiara Agnoli, Arturo Nicoletti, Antonella Fanelli, Valeria Martini, Francesco Bertoni, Laura Marconato
Summary: Canine Burkitt-like lymphoma (B-LL) is a rare tumor in dogs classified as a high-grade B-cell malignancy. Compared to the human counterpart, phenotypical differences are observed, and despite treatment, prognosis remains poor. However, around 30% of dogs can survive more than 1 year.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Hematology
Afua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, Valdemar Priebe, Luciano Cascione, Eugenio Gaudio, Chiara Tarantelli, Elisa Civanelli, Luca Aresu, Andrea Rinaldi, Giovanna Damia, Emanuela Lovati, Emanuele Zucca, Anastasios Stathis, Claudio Pietra, Francesco Bertoni
Summary: HDAC inhibitors, including Pracinostat, show distinct antitumor activity in different metabolic subtypes of DLBCL cells. Our study provides novel insights into the differential response of DLBCL metabolic subtypes to Pracinostat.
Article
Immunology
Lorenzo Spagnuolo, Viola Puddinu, Noemie Boss, Thibaud Spinetti, Anne Oberson, Jerome Widmer, Ines Mottas, Christian Hotz, Marco E. Bianchi, Mariagrazia Uguccioni, Carole Bourquin
Summary: The HMGB1-CXCL12 complex plays a crucial role in homeostasis by controlling B lymphocyte migration in the Peyer's patches. Inhibition of the complex results in reduced IgA production in the gut, indicating a novel target for controlling lymphocyte migration in mucosal immunity.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Review
Oncology
Sara Napoli, Nicolas Munz, Francesca Guidetti, Francesco Bertoni
Summary: This review provides an overview of the mechanisms by which enhancer RNAs (eRNAs) regulate gene expression, with a focus on the latest examples of dysregulated eRNAs in cancer and their involvement in the immune escape of tumor cells. eRNAs play an important role in transcriptional regulation during cellular differentiation and are induced by specific stimuli to activate target gene promoters. Dysregulation of eRNAs is common in cancer and they interact with chromatin modifiers, transcription factors, and splicing machinery. Activation of enhancers and eRNA transcription also play a significant role in inflammatory response and the interaction between cancer and immune cells.
Article
Chemistry, Multidisciplinary
Sandra Hocevar, Viola Puddinu, Laetitia Haeni, Alke Petri-Fink, Julia Wagner, Montserrat Alvarez, Martin James David Clift, Carole Bourquin
Summary: This study found that polymer-coated gold nanoparticles mainly interact with a subpopulation of B cells called age-associated B cells. However, they do not affect the percentages of other B cell populations or immune responses. These findings suggest that gold nanoparticles may be a safe tool for targeted therapy.
Article
Medicine, General & Internal
Francesca Guidetti, Alberto J. Arribas, Giulio Sartori, Filippo Spriano, Laura Barnabei, Chiara Tarantelli, Reinhard Von Roemeling, Elizabeth Martinez, Emanuele Zucca, Francesco Bertoni
Summary: Inhibitors of PI3K and BTK have limited success in inducing complete responses in indolent B cell lymphomas, suggesting the need for combination therapies. The IRAK4 inhibitor emavusertib shows effectiveness as a single agent and in combination with targeted agents, including overcoming resistance to BTK and PI3K inhibitors. Emavusertib exerts its activity through inhibition of NF-kappa B signaling and induction of apoptosis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Carmen de Ramon Ortiz, Sisi Wang, Anastasios Stathis, Francesco Bertoni, Thorsten Zenz, Urban Novak, Federico Simonetta
Summary: About one third of DLBCL patients experience relapsing/refractory disease after first line chemo-immunotherapy. CAR T cell therapy targeting CD19 is a game changer in the treatment of R/R DLBCL and shows promising results. However, the timing and sequencing of different anti-CD19-targeting therapies and their impact on subsequent CAR T cell treatment is still unclear.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Nicolas Munz, Luciano Cascione, Luca Parmigiani, Chiara Tarantelli, Andrea Rinaldi, Natasa Cmiljanovic, Vladimir Cmiljanovic, Rosalba Giugno, Francesco Bertoni, Sara Napoli
Summary: Under stressful conditions, cells activate a rescue program modulated by mTOR and rely on microRNAs and lncRNAs for translation regulation. Upregulation of lncRNA lncTNK2-2:1 may be associated with the stabilization of translation and DNA damage regulation in response to treatment with bimiralisib.
Article
Biochemistry & Molecular Biology
Andrea Unzue, Claudia Jessen-Trefzer, Dimitrios Spiliotopoulos, Eugenio Gaudio, Chiara Tarantelli, Jing Dong, Hongtao Zhao, Johanna Pachmayr, Stefan Zahler, Elena Bernasconi, Giulio Sartori, Luciano Cascione, Francesco Bertoni, Pawel Sledz, Amedeo Caflisch, Cristina Nevado
RSC MEDICINAL CHEMISTRY
(2020)
Article
Hematology
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, Luciano Cascione, Filippo Spriano, Ivo Kwee, Alberto J. Arribas, Andrea Rinaldi, Thibaud Jourdan, Melanie Berthold, Andrea Sturz, Carolyn Sperl, Francesco Margheriti, Lorenzo Scalise, Giuseppe Gritti, Davide Rossi, Anastasios Stathis, Ningshu Liu, Emanuele Zucca, Oliver Politz, Francesco Bertoni
Article
Oncology
Francesca Ricci, Federica Guffanti, Roberta Affatato, Laura Brunelli, Pastorelli Roberta, Robert Fruscio, Patrizia Perego, Maria Rosa Bani, Giovanna Chiorino, Andrea Rinaldi, Francesco Bertoni, Maddalena Fratelli, Giovanna Damia
AMERICAN JOURNAL OF CANCER RESEARCH
(2020)
